Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab AS's gross profit for the
three
months ended in Jun. 2026 was kr6,951 Mil. Genmab AS's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was kr24,686 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Genmab AS's gross profit for the
three
months ended in Jun. 2026 was kr6,951 Mil. Genmab AS's Revenue for the
three
months ended in Jun. 2026 was kr7,496 Mil. Therefore, Genmab AS's Gross Margin % for the quarter that ended in Jun. 2026 was 92.73%.
Genmab AS had a gross margin of 92.73% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Genmab AS was 98.62%. The lowest was 93.03%. And the median was 95.42%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genmab AS had a gross margin of 92.73% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Genmab AS Gross Profit Related Terms
Genmab AS Gross Profit Historical Data
* Premium members only.
The historical data trend for Genmab AS's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, MRNA: Gross Profit Comparison
For the Biotechnology subindustry, Genmab AS's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Gross Profit distribution charts can be found below:
* The bar in red indicates where Genmab AS's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr24,686 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genmab AS (CHIX:GMABC) has a Gross Profit of kr24,686 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Genmab AS and its competitors.
Is Genmab AS's Gross Profit too high?
Genmab AS's current Gross Profit is kr24,686 Mil. Overall, Genmab AS has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Gross Profit compare to VRTX and REGN?
Genmab AS's Gross Profit of kr24,686 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Genmab AS and its competitors. Genmab AS's current Gross Profit is kr24,686 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,359.87, compared to a current price of kr2,179.00 — trading 7.7% below its estimated fair value. The current Gross Profit is kr24,686 Mil. Genmab AS's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Gross Profit is kr24,686 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,179.00 is trading 7.7% below its estimated GF Value™ of kr2,359.87.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
Gross Profit: kr24,686 Mil
GF Value™: kr2,359.87 vs. price of kr2,179.00 (7.7% below fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
96GF Score
Get the complete analysis for CHIX:GMABC
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
